David J. Allsup

Kingston Upon Hull, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma

Published: June 21, 2026

Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta-Analysis.

Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta-Analysis.

Journal: European journal of haematology

Published: April 09, 2026

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

Journal: British journal of haematology

Published: April 02, 2026

A case of immune thrombocytopenia complicated by catastrophic antiphospholipid antibody syndrome and subsequent intramuscular haemorrhage.

A case of immune thrombocytopenia complicated by catastrophic antiphospholipid antibody syndrome and subsequent intramuscular haemorrhage.

Journal: Journal of medical case reports

Published: March 29, 2026

Editor's Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia.

Editor's Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia.

Journal: Cancer research

Published: March 23, 2026

Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter?

Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter?

Journal: Leukemia & lymphoma

Published: March 04, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.

Journal: European journal of haematology

Published: January 21, 2026

Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.

Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.

Journal: Leukemia

Published: December 12, 2025

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Journal: British journal of haematology

Published: December 08, 2025

Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.

Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.

Journal: Expert review of anticancer therapy

Published: November 13, 2025

Showing 1-12 of 83

Last Updated: 09/26/2026